Sagimet Biosciences

Developer of inhibitor-based drugs for treating cancer and dysfunctional metabolic diseases

placeSan Mateo, California, United States calendar_todayFounded 2007 groups10 employees language sagimet.com

Registered entities

Innovation

15 patent families (8 granted) — focus: Human necessities, Chemistry & metallurgy, Physics & computing; filing pace steady. Cited 454 times.

YearFilings
20151
20171
20181
20192
20202
20214
20227
20234
20244
20256
20264

Social engagement

Social engagement: 4.6K social following, 8 posts in the last 12 months — below the industry typical range.

Investor mix

10 investors on record; lead investors include Ascletis, Kleiner Perkins, New Enterprise Associates, Rock Springs Capital; 1 has since exited.

Investor typeCountShare
Venture capital660%
Private equity330%
Other / undisclosed110%

Recent activity

1 Jul 2026
Milestone
regulatory
28 Apr 2026
Event
Virtual KOL event
17 Dec 2025
Partnership
TAPI
Coming soon